Sector
PharmaceuticalsOpen
₹2.14Prev. Close
₹2.14Turnover(Lac.)
₹1.92Day's High
₹2.14Day's Low
₹2.0452 Week's High
₹7.6552 Week's Low
₹1.9Book Value
₹1.23Face Value
₹1Mkt Cap (₹ Cr.)
8.32P/E
0EPS
0Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 4 | 4 | 4 | 4 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 0.72 | 0.4 | -0.17 | -0.63 |
Net Worth | 4.72 | 4.4 | 3.83 | 3.37 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 9.14 | 9.22 | 9.42 | 6.44 |
yoy growth (%) | -0.82 | -2.18 | 46.4 | 85.35 |
Raw materials | -8.48 | -8.56 | -9.13 | -5.52 |
As % of sales | 92.71 | 92.83 | 96.88 | 85.85 |
Employee costs | -0.11 | -0.29 | -0.25 | -0.1 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 0.46 | 0.14 | -0.2 | 0.26 |
Depreciation | 0 | 0 | 0 | 0 |
Tax paid | 0 | -0.04 | 0 | -0.02 |
Working capital | 4.72 | 0.09 | -1.25 | 0.48 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -0.82 | -2.18 | 46.4 | 85.35 |
Op profit growth | -61.07 | -141.68 | -147.48 | -495.32 |
EBIT growth | 41.27 | 166.09 | -63.7 | -651.11 |
Net profit growth | 364.35 | -149 | -184.9 | -251.1 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 27.84 | 17.81 | 10.4 | 9.89 | 9.62 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 27.84 | 17.81 | 10.4 | 9.89 | 9.62 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 0.05 | 0.48 | 0.83 | 0.51 | 0.57 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,766.2 | 134.52 | 4,23,770.54 | 1,181.05 | 0.76 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,958.35 | 76.3 | 1,58,175.47 | 594 | 0.5 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,486.75 | 25.8 | 1,20,075.94 | 1,438.15 | 0.87 | 4,134.87 | 360.72 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,183 | 59.05 | 1,07,722.35 | 485 | 0.88 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,434.1 | 51.93 | 1,00,425.74 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Non Executive Director
Hemant Parikh
Managing Director
Jayendra Mehta
Independent Director
Rina Kumari
Independent Director
Shah A P
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Vivanza Biosciences Ltd
Summary
Vivanza Biosciences Ltd (Previously known Ivee Injectaa Limited) was established in March, 1982 as a Private Limited Company and was converted into a Public Limited Company in May, 1992. Head quartered in Gujarat, India, the Company came into existence in April 2016 with the sole aim to further spread its wings in global market with global quality pharmaceutical products at competitive pricing system.The Company is presently engaged in the business of Pharmaceutical Products and Pharma Products.However Competition in the industry is continuously increasing. New technology is being adopted and steps are taken to improve the manufacturing capacity of the Company. Further, the Company has also set its vision in global market to supply and execute turnkey pharmaceutical units.The company undertook an expansion-cum-diversification programme to increase its capacity from 18 lac pa to 54 lac pa. It also proposed to diversify into the manufacture of small volume parenterals with an installed capacity of 294 lac pa. It came out with a public issue of 21,70,000 equity shares of Rs 10 each for cash at par aggregating Rs 217 lac. It is one of the few companies which has facilities for both glass as well as plastic containers. Due to recessionary trends which lead to difficult business conditions in the year 1999-2000, the parenteral industry suffered a setback. As a result of this, the name of the Company was changed from Ivee Injectaa Ltd. to Vivanza Biosciences Ltd in 2015.The Company
Read More
The Vivanza Biosciences Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is ₹2.08 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Vivanza Biosciences Ltd is ₹8.32 Cr. as of 09 May ‘25
The PE and PB ratios of Vivanza Biosciences Ltd is 0 and 1.73 as of 09 May ‘25
The 52-week high/low is the highest and lowest price at which a Vivanza Biosciences Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Vivanza Biosciences Ltd is ₹1.9 and ₹7.65 as of 09 May ‘25
Vivanza Biosciences Ltd's CAGR for 5 Years at 11.35%, 3 Years at -51.62%, 1 Year at -69.08%, 6 Month at -50.12%, 3 Month at -1.83% and 1 Month at -4.04%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.